Patrizia Racca

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Giulia Siravegna, Benedetta Mussolin, Michela Buscarino et al. · Nature Medicine · 2015 · 1.1K citations · Full text

Medicine, Cancer Biology, Oncology +16

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016 · 1K citations · Full text

Medicine, Oncology, Pharmacology +14

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

Emanuele Valtorta, Cosimo Martino, Andrea Sartore‐Bianchi et al. · Modern Pathology · 2015 · 317 citations · Full text

Medicine, Oncology, Pathology +13

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

Ludovic Barault, Alessio Amatu, Giulia Siravegna et al. · Gut · 2017 · 238 citations · Full text

Medicine, Molecular Biology, Oncology +17